{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:03Z","timestamp":1792194963394,"version":"4.4.0"},"reference-count":167,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2653369","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T19:04:31Z","timestamp":1776884671000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1247-4783","authenticated-orcid":false,"given":"Walter","family":"Straus","sequence":"first","affiliation":[{"name":"Moderna, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_3_7_2_1","unstructured":"Centers for Disease Control and Prevention. COVID-19 data tracker: deaths. 2025."},{"key":"e_1_3_7_3_1","unstructured":"European Centre for Disease Prevention and Control. Risk assessment: outbreak of acute respiratory syndrome associated with a novel coronavirus Wuhan China; first update \u2013 22 January 2020. 2022."},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191"},{"key":"e_1_3_7_5_1","unstructured":"U.S. Department of Health and Human Services. Office of the Assistant Secretary for Preparedness and Response. Determination that a public health emergency exists nationwide as the result of the 2019 novel coronavirus. 2020."},{"key":"e_1_3_7_6_1","unstructured":"World Health Organisation. Middle East respiratory syndrome coronavirus (MERS-CoV). 2025."},{"key":"e_1_3_7_7_1","unstructured":"Centers for Disease Control and Prevention. Update: Severe acute respiratory syndrome \u2014 worldwide and United States 2003. 2003."},{"key":"e_1_3_7_8_1","unstructured":"World Health Organization. COVID-19 public health emergency of international concern (PHEIC). Global research and innovation forum: towards a research roadmap. 2020."},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.085"},{"key":"e_1_3_7_11_1","volume-title":"The Conversation","author":"McQueen M","year":"2020","unstructured":"McQueen M. Coronavirus control measures aren\u2019t pointless \u2013 just slowing down the pandemic could save millions of lives. The Conversation. 2020 Mar 11. https:\/\/theconversation.com\/coronavirus-control-measures-arent-pointless-just-slowing-down-the-pandemic-could-save-millions-of-lives-13346."},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00399-6"},{"key":"e_1_3_7_13_1","unstructured":"World Health Organization. What we know about COVID-19 vaccine development. 2020."},{"key":"e_1_3_7_14_1","unstructured":"Smith D. Trump unveils \u2018warp-speed\u2019 effort to create coronavirus vaccine by year\u2019s end. The guardian. 2020."},{"key":"e_1_3_7_15_1","unstructured":"U.S Government Accountability Office. Operation Warp Speed: Accelerated COVID-19 vaccine development status and efforts to address manufacturing challenges. 2021."},{"key":"e_1_3_7_16_1","volume-title":"Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders. U.S. Department of Health and Human Services; 2017."},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8920"},{"key":"e_1_3_7_18_1","unstructured":"U.S. Department of Health and Human Services. Explaining operationWarp speed. 2020."},{"key":"e_1_3_7_19_1","unstructured":"U.S. Food and Drug Administration. FDA in brief: FDA issues guidance on emergency use authorization for COVID-19 vaccines. 2020."},{"key":"e_1_3_7_20_1","volume-title":"Evidence review of the adverse effects of COVID-19 vaccination and intramuscular vaccine administration. Bass AR, Stratton K, Kumova OK, Rosenberg D","author":"National Academies of Sciences Engineering Medicine","year":"2024","unstructured":"National Academies of Sciences Engineering Medicine. Evidence review of the adverse effects of COVID-19 vaccination and intramuscular vaccine administration. Bass AR, Stratton K, Kumova OK, Rosenberg D, Eds. Washington (DC): The National Academies Press; 2024."},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3918"},{"key":"e_1_3_7_22_1","unstructured":"COVID-19 Prevention Network (CoVPN) National Institute of Allergy and Infectious Diseases National Institutes of Health. About Covpn. 2025."},{"key":"e_1_3_7_23_1","volume-title":"Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration. FDA briefing document: Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee Meeting; December 17, 2020; Silver Spring, MD. 2020."},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2027405"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243"},{"key":"e_1_3_7_26_1","unstructured":"Zhang Y. Wuhan seafood market pneumonia virus \u2013 whole genome sequence. 2020."},{"key":"e_1_3_7_27_1","volume-title":"Moderna announces first participant dosed in NIH led phase 1 study of mRNA vaccine (mRNA 1273) against novel coronavirus","author":"Moderna, Inc","year":"2020","unstructured":"Moderna, Inc. Moderna announces first participant dosed in NIH led phase 1 study of mRNA vaccine (mRNA 1273) against novel coronavirus. U.S. Securities and Exchange Commission; 2020."},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024671"},{"key":"e_1_3_7_30_1","unstructured":"U.S. Food & Drug Administration. Considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications: guidance for industry. 2006."},{"key":"e_1_3_7_31_1","volume-title":"Center for biologics evaluation and review. Development and licensure of vaccines to prevent COVID-19: guidance for industry (Docket No. FDA-2020-D-1137)","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration. Center for biologics evaluation and review. Development and licensure of vaccines to prevent COVID-19: guidance for industry (Docket No. FDA-2020-D-1137). U.S. Department of Health and Human Services; 2023."},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103916"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.02.007"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028436"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_3_7_38_1","unstructured":"Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 17 2020. 2020."},{"key":"e_1_3_7_39_1","unstructured":"U.S. Food and Drug Administration. Vaccines and related biological products advisory committee meeting: December 17 2020 \u2013 meeting minutes. Center for Biologics Evaluation and Research U.S. Department of Health and Human Services; 2020."},{"key":"e_1_3_7_40_1","unstructured":"U.S. Food and Drug Administration. Vaccines and related biological products advisory committee meeting June 14-15 2022; FDA briefing document EUA amendment request for use of the Moderna COVID-19 vaccine in children 6 months through 17 years of age. 2022."},{"key":"e_1_3_7_41_1","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccine safety reporting systems. 2025."},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7131a2"},{"key":"e_1_3_7_43_1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module IX \u2013 signal management (Rev 1). 2017."},{"key":"e_1_3_7_44_1","unstructured":"Petousis-Harris H. Vaccine safety signals \u2013 what are they and what to do when you find one. Auckland (NZ): Global Vaccine Data Network; 2023."},{"key":"e_1_3_7_45_1","unstructured":"Law B Sturkenboom M. D2.3 priority list of adverse events of special interest: COVID-19 (version 1.1). Safety Platform for Emergency vACcines Coalition for Epidemic Preparedness Innovations; 2020."},{"key":"e_1_3_7_46_1","unstructured":"SPEAC\/Brighton Collaboration. SPEAC_D2.3_V2.0_COVID-19_20200525_PUBLIC.PDF. 2020 May 25. https:\/\/brightoncollaboration.org\/wp-content\/uploads\/2023\/05\/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf."},{"key":"e_1_3_7_47_1","unstructured":"CDC. MMWR: allergic reactions including anaphylaxis after Moderna COVID-19 vaccine (Dec 2020\u2013Jan 2021). https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7004e1.htm."},{"key":"e_1_3_7_48_1","unstructured":"Brighton Collaboration\/SPEAC. Updated COVID-19 AESI list. 2022 Oct. https:\/\/brightoncollaboration.org\/wp-content\/uploads\/2022\/10\/Updated-COVID-19-AESI-list_Oct2022.pdf."},{"key":"e_1_3_7_49_1","unstructured":"SPEAC\/Brighton Collaboration. SO2_D2.1.2_V1.2_COVID-19_AESI UPDATE 23Dec2020 REVIEW_FINAL.PDF. 2020 Dec 23. https:\/\/brightoncollaboration.org\/wp-content\/uploads\/2020\/06\/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf."},{"key":"e_1_3_7_50_1","unstructured":"FDA. SPIKEVAX (COVID-19 vaccine mRNA) prescribing information (2024-2025 formula) (includes dermal filler swelling; delayed injection-site reactions). 2024. https:\/\/www.fda.gov\/media\/155675\/download."},{"key":"e_1_3_7_51_1","unstructured":"Centers for Disease Control and Prevention. Flu vaccination coverage United States 2019\u201320 influenza season. 2024."},{"key":"e_1_3_7_52_1","volume-title":"Vaccines and Related Biological Products Advisory Committee meeting; June 10, 2021","author":"Anderson SA","year":"2021","unstructured":"Anderson SA. FDA updates of COVID-19 vaccine safety activities. Vaccines and Related Biological Products Advisory Committee meeting; June 10, 2021; Silver Spring, MD. 2021."},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61877-8"},{"key":"e_1_3_7_55_1","first-page":"9","volume-title":"Vaccines and related biological products advisory committee briefing document: Emergency use authorization for vaccines to prevent COVID-19","author":"U.S. Food & Drug Administration","year":"2020","unstructured":"U.S. Food & Drug Administration. Vaccines and related biological products advisory committee briefing document: Emergency use authorization for vaccines to prevent COVID-19. Silver Spring (MD). 2020. p. 9."},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.07.048"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.016"},{"key":"e_1_3_7_60_1","unstructured":"Centers for Disease Control and Prevention. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. 2021."},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800028"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00435-x"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306362"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02153.x"},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2016.78"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3283"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1096"},{"key":"e_1_3_7_69_1","unstructured":"American College of Cardiology. Cardiac implications of novel Wuhan coronavirus February 14 2020. ACC Clinical Bulletin; 2020."},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7035e5"},{"key":"e_1_3_7_71_1","unstructured":"Times of Israel. Israel said probing link between Pfizer shot and heart problem in men under 30. 2021 Apr 23. https:\/\/www.timesofisrael.com\/israel-said-probing-link-between-pfizer-shot-and-heart-problem-in-men-under-30\/."},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2833"},{"key":"e_1_3_7_73_1","unstructured":"Centers for Disease Control and Prevention Advisory Committee on Immunization Practices COVID-19 Vaccine Safety Technical (VaST) Work Group. COVID-19 vast work group report \u2013 May 17 2021. 2021."},{"key":"e_1_3_7_74_1","unstructured":"World Health Organization. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines. 2021."},{"key":"e_1_3_7_75_1","unstructured":"U.S. Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (Vaccination providers): Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). 2022."},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac446"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7027e2"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7114e1"},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27501"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00791-7"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70151"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae157"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.5511"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7107e1"},{"key":"e_1_3_7_85_1","unstructured":"U.S. Food & Drug Administration. Novavax COVID-19 vaccine adjuvanted (Nuvaxovid) \u2013 prescribing information [Package insert]. 2025."},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24110"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18505"},{"key":"e_1_3_7_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948335"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00355-5"},{"key":"e_1_3_7_91_1","volume-title":"Adverse effects of vaccines: evidence and causality","author":"Committee to Review Adverse Effects of Vaccines, Institute of Medicine, Stratton K, Ford A, Rusch E, Wright Clayton E e","year":"2011","unstructured":"Committee to Review Adverse Effects of Vaccines, Institute of Medicine, Stratton K, Ford A, Rusch E, Wright Clayton E e. Adverse effects of vaccines: evidence and causality. Washington (DC): National Academies Press; 2011."},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.017"},{"key":"e_1_3_7_93_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7018e3"},{"key":"e_1_3_7_94_1","volume-title":"Emergency use authorization of Moderna COVID-19 vaccine","author":"U.S. Department of Health and Human Services","year":"2021","unstructured":"U.S. Department of Health and Human Services. Emergency use authorization of Moderna COVID-19 vaccine. U.S. Food & Drug Administration; 2021."},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6925a1"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6944e3"},{"key":"e_1_3_7_97_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3320"},{"key":"e_1_3_7_98_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6944e2"},{"key":"e_1_3_7_99_1","unstructured":"The American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19. 2020."},{"key":"e_1_3_7_100_1","unstructured":"Mbaeyi SA. Use of Pfizer\u2013BioNTech COVID-19 vaccine: clinical considerations. Emergency meeting of the Advisory Committee on Immunization Practices Centers for Disease Control and Prevention; 2020."},{"key":"e_1_3_7_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104983"},{"key":"e_1_3_7_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15494"},{"key":"e_1_3_7_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2114466"},{"key":"e_1_3_7_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4255"},{"key":"e_1_3_7_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079364"},{"key":"e_1_3_7_106_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7101e1"},{"key":"e_1_3_7_107_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7239a3"},{"key":"e_1_3_7_108_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.1929"},{"key":"e_1_3_7_109_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.3581"},{"key":"e_1_3_7_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.019"},{"key":"e_1_3_7_111_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852928"},{"key":"e_1_3_7_112_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052286"},{"key":"e_1_3_7_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109522"},{"key":"e_1_3_7_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203315"},{"key":"e_1_3_7_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209367"},{"key":"e_1_3_7_116_1","unstructured":"U.S. Food and Drug Administration. Vaccines and related biological products advisory committee meeting June 14-15 2022. FDA briefing document. EUA amendment request for use of the Moderna COVID-19 vaccine in children 6 months through 17 years of age. 2022."},{"key":"e_1_3_7_117_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7135a3"},{"key":"e_1_3_7_118_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.801321"},{"key":"e_1_3_7_119_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058167"},{"key":"e_1_3_7_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.8192"},{"key":"e_1_3_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128225"},{"key":"e_1_3_7_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031076"},{"key":"e_1_3_7_123_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2112866"},{"key":"e_1_3_7_124_1","unstructured":"U.S. Food & Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. News release. 2021."},{"key":"e_1_3_7_125_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2111462"},{"key":"e_1_3_7_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.07.031"},{"key":"e_1_3_7_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107065"},{"key":"e_1_3_7_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42030"},{"key":"e_1_3_7_129_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005114"},{"key":"e_1_3_7_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50656-8"},{"key":"e_1_3_7_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.017"},{"key":"e_1_3_7_132_1","unstructured":"World Health Organization. COVID-19 vaccines: safety surveillance manual. 2020."},{"key":"e_1_3_7_133_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-061894"},{"key":"e_1_3_7_134_1","unstructured":"International Society of Pharmacoepidemiology (ISPE). Good pharmacoepidemiology practices (GPP). 2015."},{"key":"e_1_3_7_135_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3180616c0a"},{"key":"e_1_3_7_136_1","doi-asserted-by":"publisher","DOI":"10.1080\/07474946.2011.539924"},{"key":"e_1_3_7_137_1","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. 11th revision of the ENCePP guide on methodological standards in pharmacoepidemiology published. 2023."},{"key":"e_1_3_7_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.099"},{"key":"e_1_3_7_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2311969"},{"key":"e_1_3_7_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.09.060"},{"key":"e_1_3_7_141_1","volume-title":"International Society for Pharmacoepidemiology 2024","author":"Zwiers LC","year":"2024","unstructured":"Zwiers LC, Stuurman AL, Collaboration VE. Myocarditis\/pericarditis after Spikevax\u2014multi-country cohort results. International Society for Pharmacoepidemiology 2024. 2024."},{"key":"e_1_3_7_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.100"},{"key":"e_1_3_7_143_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae067"},{"key":"e_1_3_7_144_1","article-title":"Safety monitoring of multiple health outcomes following 2023\u20132024 COVID-19 vaccination among Medicare beneficiaries aged 65 years and older in the United States","author":"Gruber JF","year":"2025","unstructured":"Gruber JF, Ondari M, Zelaya CE, Xia, C, Zhang, F, Hervol, JR, Ye, J, Chen, M, Qin, Y, Hu, M, et al. Safety monitoring of multiple health outcomes following 2023\u20132024 COVID-19 vaccination among Medicare beneficiaries aged 65 years and older in the United States. medRxiv. 2025;2025.2001.2003.25319975.","journal-title":"medRxiv"},{"key":"e_1_3_7_145_1","volume-title":"Advisory Committee on Immunization Practices (ACIP) meeting","author":"Meyer SA","year":"2025","unstructured":"Meyer SA, Prevention CfDCa. Update on CDC\u2019s COVID-19 vaccine safety monitoring. Advisory Committee on Immunization Practices (ACIP) meeting; Atlanta, GA. 2025."},{"key":"e_1_3_7_146_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840"},{"key":"e_1_3_7_147_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7017e4"},{"key":"e_1_3_7_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"e_1_3_7_149_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e4"},{"key":"e_1_3_7_150_1","volume-title":"Interpretation & next steps \u2013 Advisory Committee on Immunization Practices meeting, February 24, 2023","author":"Twentyman E","year":"2023","unstructured":"Twentyman E, U.S. Centers for Disease Control and Prevention. Ischemic stroke, COVID-19 and influenza in adults ages \u226565 years. Interpretation & next steps \u2013 Advisory Committee on Immunization Practices meeting, February 24, 2023; Atlanta, GA. 2023."},{"key":"e_1_3_7_151_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.1059"},{"key":"e_1_3_7_152_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.10123"},{"key":"e_1_3_7_153_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2302134"},{"key":"e_1_3_7_154_1","volume-title":"Advisory Committee on Immunization Practices meeting","author":"Centers for Disease Control and Prevention","year":"2023","unstructured":"Centers for Disease Control and Prevention. Update on COVID-19 and influenza vaccine safety. Advisory Committee on Immunization Practices meeting; Atlanta, GA. 2023."},{"key":"e_1_3_7_155_1","unstructured":"U.S. Food and Drug Administration. Package insert Spikevax. 2025."},{"key":"e_1_3_7_156_1","doi-asserted-by":"crossref","unstructured":"Hl\u00e1vka J Rose A. COVID-19\u2019s total cost to the U.S. economy will reach $14 trillion by end of 2023. 2023.","DOI":"10.64628\/AAI.ttgaaumnk"},{"key":"e_1_3_7_157_1","unstructured":"Akpan N. Why a coronavirus vaccine could take way longer than a year. National geographic. 2020."},{"key":"e_1_3_7_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2007.06.013"},{"issue":"5","key":"e_1_3_7_159_1","first-page":"1\u201322; quiz CE21","article-title":"Advisory committee on immunization p. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Prevots DR","year":"2000","unstructured":"Prevots DR, Burr RK, Sutter RW, Murphy TV. Advisory committee on immunization p. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR\u20135):1\u201322; quiz CE21\u201327.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"e_1_3_7_160_1","first-page":"1\u201330; quiz CE32","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz R","year":"2008","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices, U.S. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2008;57(RR\u20135):1\u201330; quiz CE32\u201334.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_7_161_1","unstructured":"Schuchat A Marks P. Centers for Disease Control and Prevention. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. 2021."},{"key":"e_1_3_7_162_1","unstructured":"U.S. Food and Drug Administration. Letter authorizing revision of the Janssen COVID-19 vaccine emergency use authorization (addition of thrombosis with thrombocytopenia syndrome warning). 2021."},{"key":"e_1_3_7_163_1","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccine safety technical (VaST) work group report June 28 2021. 2021."},{"key":"e_1_3_7_164_1","unstructured":"U.S. Food and Drug Administration. Fda news release \u2014 Coronavirus (COVID-19) update: July 13 2021. 2021."},{"issue":"27","key":"e_1_3_7_165_1","first-page":"577","article-title":"Intussusception among recipients of rotavirus vaccine\u2013United States, 1998-1999","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","unstructured":"Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine\u2013United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577\u2013581.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"e_1_3_7_166_1","first-page":"1007","article-title":"Withdrawal of rotavirus vaccine recommendation","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","unstructured":"Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48(43):1007.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_7_167_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1113003"},{"key":"e_1_3_7_168_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01639-4"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2653369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:39:00Z","timestamp":1778179140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2653369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2653369"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2653369","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2653369"}}